drugset / Trial / NCT02672488
Metformin Plus Sorafenib for Advanced HCC
Phase 2
Unknown
82 enrolled
Tianjin Medical University Cancer Institute and Hospital
First Affiliated Hospital of Harbin Medical University · collabFudan University · collabHarbin Medical University · collabLiaoning Cancer Hospital & Institute · collabShanghai Zhongshan Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Metformin is a widely used oral drug for type 2 diabetes and its antitumor effects have got much more attentions recently. It has been shown that metformin exerts anti-cancer activities in several cancers, including primary liver cancer. In this phase II study, safety and efficacy of the combination of metformin and sorafenib will be evaluated in patients with advanced hepatocellular carcinoma.
Timeline
- Start
- 2015-12
- Primary completion
- 2017-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 500 mg | Oral |
| Background | Sorafenib | Small molecule | 400 ug | Oral |